Published in Cell Cycle on February 16, 2010
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53. Cell Cycle (2013) 0.97
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol (2010) 0.95
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget (2013) 0.86
Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Oncotarget (2015) 0.86
Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget (2014) 0.79
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. Cell Cycle (2016) 0.77
Identification of rictor as a novel substrate of Polo-like kinase 1. Cell Cycle (2015) 0.77
Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition. Oncotarget (2015) 0.76
SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors. Cell Cycle (2010) 0.76
Actinobacillus pleuropneumoniae induces SJPL cell cycle arrest in G2/M-phase and inhibits porcine reproductive and respiratory syndrome virus replication. Virol J (2015) 0.75
Freezing Polo in its sleep: targeting the inactive conformation of Polo-like kinase 1 in cancer cells. Cell Cycle (2010) 0.75
Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells. Oncotarget (2016) 0.75
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov (2011) 4.16
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Polo-like kinases and oncogenesis. Oncogene (2005) 2.86
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol (2008) 2.37
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
Fate of primary cells at the G₁/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle (2011) 2.11
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J Chem Inf Comput Sci (2003) 2.02
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
PocketPicker: analysis of ligand binding-sites with shape descriptors. Chem Cent J (2007) 1.90
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Brief report: tracheal intubation using the Bonfils intubation fibrescope or direct laryngoscopy for patients with a simulated difficult airway. Can J Anaesth (2008) 1.82
Support vector machine applications in bioinformatics. Appl Bioinformatics (2003) 1.78
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol (2012) 1.75
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J Med Chem (2002) 1.63
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. EMBO Rep (2010) 1.54
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. J Biol Chem (2004) 1.52
Prediction of type III secretion signals in genomes of gram-negative bacteria. PLoS One (2009) 1.50
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Effect of humidified and heated CO2 during gynecologic laparoscopic surgery on analgesic requirements and postoperative pain. J Am Assoc Gynecol Laparosc (2004) 1.48
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat (2009) 1.38
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol (2010) 1.33
Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol (2002) 1.32
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res (2008) 1.31
An unusual ERAD-like complex is targeted to the apicoplast of Plasmodium falciparum. Eukaryot Cell (2009) 1.31
Distinct roles of secreted HtrA proteases from gram-negative pathogens in cleaving the junctional protein and tumor suppressor E-cadherin. J Biol Chem (2012) 1.31
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity (2010) 1.29
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist (2012) 1.29
Properties and prediction of mitochondrial transit peptides from Plasmodium falciparum. Mol Biochem Parasitol (2003) 1.28
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast (2004) 1.21
Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials (2006) 1.20
SATB1 gene expression and breast cancer prognosis. Breast (2010) 1.18
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis (2009) 1.15
Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol (2010) 1.13
Impact of conformational flexibility on three-dimensional similarity searching using correlation vectors. J Chem Inf Model (2006) 1.13
Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J Biol Chem (2008) 1.12
Processing and classification of chemical data inspired by insect olfaction. Proc Natl Acad Sci U S A (2007) 1.12
Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol (2006) 1.12
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun (2011) 1.12
Predicting olfactory receptor neuron responses from odorant structure. Chem Cent J (2007) 1.12
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res (2009) 1.12
Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep (2008) 1.10
Prediction of extracellular proteases of the human pathogen Helicobacter pylori reveals proteolytic activity of the Hp1018/19 protein HtrA. PLoS One (2008) 1.10
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res (2006) 1.10
Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle (2006) 1.10
A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem (2002) 1.10
Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res (2006) 1.09
Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target (2004) 1.08
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res (2007) 1.07
Voyages to the (un)known: adaptive design of bioactive compounds. Trends Biotechnol (2008) 1.06
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem (2006) 1.04
A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem (2009) 1.04
Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity. Mol Cell Biol (2010) 1.03
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
Polo-like kinase 1-mediated phosphorylation stabilizes Pin1 by inhibiting its ubiquitination in human cells. J Biol Chem (2005) 1.03
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol (2011) 1.03
Kernel approach to molecular similarity based on iterative graph similarity. J Chem Inf Model (2007) 1.03